TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06444178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN9933
Description: Administered intravenous (IV)
Study: NCT05152836

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrotactile stimulation at tremor frequency
Description: Mechanical vibrations are applied at brief bursts of 80Hz that occur at the individual tremor frequency. Vibrations are delivered via a small device, which is worn on the wrist of the most-affected arm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrotactile stimulation at tremor frequency*1.5
Description: Mechanical vibrations are applied at 80Hz bursts at individual tremor frequency\*1.5. Vibrations are delivered via a small device, which is worn on the wrist of the most-affected arm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrotactile stimulation at continuous stimulation
Description: Continuous 80Hz stimulation is applied via a small device worn on the wrist of the most-affected arm.
Study: NCT06444178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7508
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Oral administration
Study: NCT05794698

Intervention type: PROCEDURE
Intervention: Surgical resection
Description: Surgical resection of lung adenocarcinoma. Wedge resection, segmentectomy or lobectomy will be performed according to each patients' condition.
Study: NCT06490367

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-Restricted Eating Diet
Description: Participants engage in a time-restricted eating diet, specifically maintaining a 6-8-hour eating window every day for 12 weeks. Participants are allowed to self-select the timing of the eating window, but once selected, they are asked to maintain that schedule daily. Outside of that window, for the remaining 16-18 hours of day/night, participants are asked not to consume calorie-containing food or drink. Beverages without calories are allowed.
Study: NCT04003896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Participant will take 200 mg capsules or tablets orally twice daily. The participant will be instructed to swallow abemaciclib as a whole tablet and not to chew, crush or split capsules or tablets before swallowing. Participants should not ingest abemaciclib tablets if broken, cracked, or otherwise not intact. Doses should be taken at a approximately the same time every day, twice daily. Capsules or tablets can be taken orally with or without food. If the participant vomits or misses a dose of abemaciclib, the participant will be instructed to take the next dose at its scheduled time.~Participants will also be provided with a diary and instructed to keep a twice daily record of the times they have taken their medications and any other events such as vomiting, diarrhea, etc.
Study: NCT05637736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction by Therapeutic VR
Description: Therapeutic VR+MBT was provided using a head-mounted display which designed to enclose eyes and block external stimuli almost entirely. Patients can see immersive natural scenes through VR devices and hear stereo sounds through headphones. We uploaded a programme, which was designed to induce recordings of guided meditations (The same as the MBT), musics for meditation and consists of meditation-videos of 40 minutes. We will guide patients to choose their favorite meditation videos, such as forest, seaside, lake, snow mountain, field and so on.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-based Stress Reduction
Description: 39 participates randomized and allocated to this group. MBT was conducted as an 8-week group intervention. Sessions typically began with formal mindfulness meditations that include breathing exercises, prolonged expiratory relaxation, body scan, and meditation. MBT was delivered by the first author, who has specialized training in mindfulness meditation.
Study: NCT06581991

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Valine oral solution (50mg/ml) and isoleucine oral solution (25mg/ml)
Description: Subjects will take valine oral solution (50mg/ml) in place of usual powdered valine supplement for 28 days. Subjects will then take isoleucine oral solution (25mg/ml) in place of their usual powdered isoleucine supplement for 28 days.
Study: NCT05160740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green for injection
Description: ICG will be injected to participants preoperatively for molecular fluorescence image

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Indocyanine green for injection
Description: ICG will be injected to participants preoperatively for molecular fluorescence image
Study: NCT06553352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib combined with Obinutuzumab
Description: Zanubrutinib combined with Obinutuzumab (ZO), a specific dose on specific days.
Study: NCT05387317

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfizer-BioNTech Standard dose
Description: Standard Dose - (30ug in 0.3ml)~The Pfizer-BioNTech COVID-19 vaccine, BNT162b2, encodes a P2 mutant spike protein and is formulated as an RNA-lipid nanoparticle (LNP) of nucleoside-modified mRNA (modRNA).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfizer-BioNTech Standard dose
Description: Standard Dose - (30ug in 0.3ml)~The Pfizer-BioNTech COVID-19 vaccine, BNT162b2, encodes a P2 mutant spike protein and is formulated as an RNA-lipid nanoparticle (LNP) of nucleoside-modified mRNA (modRNA).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AstraZeneca Standard dose
Description: Standard Dose (5xE10vp in 0.5ml)~ChAdOx1 nCoV-19 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 spike (S) surface glycoprotein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AstraZeneca Standard dose
Description: Standard Dose (5xE10vp in 0.5ml)~ChAdOx1 nCoV-19 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 spike (S) surface glycoprotein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfizer-BioNTech Fractional dose
Description: Fractional Dose - (15ug in 0.15ml)~The Pfizer-BioNTech COVID-19 vaccine, BNT162b2, encodes a P2 mutant spike protein and is formulated as an RNA-lipid nanoparticle (LNP) of nucleoside-modified mRNA (modRNA).
Study: NCT05146648

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gondola AMPS
Description: One treatment session lasts about two minutes and consists of the application of a mechanical pressure pulses on each of the points, one after the other, for a set duration (a few seconds), which is repeated several times in sequence.
Study: NCT05387317

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfizer-BioNTech Fractional dose
Description: Fractional Dose - (15ug in 0.15ml)~The Pfizer-BioNTech COVID-19 vaccine, BNT162b2, encodes a P2 mutant spike protein and is formulated as an RNA-lipid nanoparticle (LNP) of nucleoside-modified mRNA (modRNA).
Study: NCT05146648

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Gondola AMPS
Description: One treatment session lasts about two minutes and consists of the application of a mechanical pressure pulses on each of the points, one after the other, for a set duration (a few seconds), which is repeated several times in sequence.
Study: NCT04725851

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High concentration Oxygen therapy
Description: FiO2 \>80% Oxygen (Delivered with 12-15L/min Non-rebreather Mask)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control: Room Air or Low concentration Oxygen
Description: FiO2 \<30% Oxygen (Delivered with 0-2L/min Nasal Cannula)
Study: NCT05387317

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AstraZeneca Fractional dose
Description: Fractional Dose (2.5E10vp in 0.25ml)~ChAdOx1 nCoV-19 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 spike (S) surface glycoprotein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AstraZeneca Fractional dose
Description: Fractional Dose (2.5E10vp in 0.25ml)~ChAdOx1 nCoV-19 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 spike (S) surface glycoprotein
Study: NCT05152836

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrotactile stimulation 10% below and above step frequency
Description: This intervention is applied during assessment of gait. Two devices are worn on both ankles which allows alternating stimulation of both ankles with brief bursts of 80 HZ at the individual step frequency plus or minus 10%.
Study: NCT05387317

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna Standard dose
Description: Standard dose (50ug in 0.25ml)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna Standard dose
Description: Standard dose (50ug in 0.25ml)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna Fractional dose
Description: Fractional dose (20ug in 0.1ml)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna Fractional dose
Description: Fractional dose (20ug in 0.1ml)
Study: NCT04659603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tusamitamab ravtansine
Description: Pharmaceutical form:Concentrated solution for IV;~Route of administration: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tusamitamab ravtansine
Description: Pharmaceutical form:Concentrated solution for IV;~Route of administration: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tusamitamab ravtansine
Description: Pharmaceutical form:Concentrated solution for IV;~Route of administration: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Pharmaceutical form: Lyophilized powder for reconstitution or as a solution for infusion;~Route of administration: IV infusion
Study: NCT05614375

Intervention type: PROCEDURE
Intervention: endoscopic surgery
Description: transnasal endoscopic surgery
Study: NCT05737355

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ANKASCIN 568-P Red yeast rice capsules
Description: Product ingredients: ANKASCIN 568-P red yeast rice product 440 mg,microcrystalline ,cellulose,Maltodextrin; capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum.
Study: NCT06322329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic MRI
Description: Subjects receive a study-specific dynamic MRI scan. If the hypothesis of the study is confirmed, this examination can be used to inform future patients' treatment planning, replacing the use of 4D CT.
Study: NCT06160531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-42344
Description: Anti-influenza A agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-42344
Description: Anti-influenza A agent

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT05737355

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules
Description: Maltodextrin was used as a placebo
Study: NCT05275647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX 100U in normal saline
Description: LESW with 3000 shocks, frequency of 3 pulses per second, and maximum total energy flow density 0.25 mJ/mm2 , and followed by intravesical BoNT-A 100U instillation in 30ml normal saline retained in the bladder for 2 hours, every one week for 4 times.
Study: NCT06021912

Intervention type: DRUG
Intervention: Immunotherapy
Description: Sublingual immunotherapy

Intervention type: DRUG
Intervention: Immunotherapy
Description: Sublingual immunotherapy
Study: NCT05331547

Intervention type: DEVICE
Intervention: BioFreedom BA9 (SS) Ultra DCS
Description: BioFreedom Ultra stent for treatment of STEMI patients. Besides, in patients who are clinically indicated for a stage procedure, we aim to assess the angiographic and endovascular healing of BioFreedom Ultra stent at one month
Study: NCT05441124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfullness Based Stress Reduction (MBSR) intervention
Description: Mindfullness Based Stress Reduction (MBSR) intervention: Monitoring stress and anxiety levels with mindfulness program
Study: NCT05275647

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: LESW treatment with 3000 shocks, frequency of 3 pulses per second, and maximum total energy flow density 0.25 mJ/mm2 , and followed by intravesical instillation of 30ml normal saline retained in the bladder for 2 hours after LESW application, every one week for 4 times.
Study: NCT05992597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZR2 RDHAP
Description: ZR2:Rituximab 375mg/m2, D1, Lenalidomide 24mg qd D1-14, zebutinib 160mg bid RDHAP:Rituximab 375mg/m2 D0, dexamethasone 40mg D1-4, cytarabine 2g/m2 q12h D2, cisplatin 25mg/m2 D1-3.
Study: NCT04175769

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional supplement
Description: Subjects will orally consume two gelatin capsules of nutritional supplement (1 gram), 2 times per day with meals, and 1 capsule at one additional meal or snack, totaling five capsules per day beginning the first day of treatment and continuing for the duration of their treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will orally consume two gelatin capsules of placebo (1 gram), 2 times per day with meals, and 1 capsule at one additional meal or snack, totaling five capsules per day beginning the first day of treatment and continuing for the duration of their treatment.
Study: NCT04840134

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: From Hardship to Hope: A Peer-led intervention to reduce financial hardship and suicide risk
Description: The intervention will be delivered in two consecutive phases:~1. Intensive Intervention Phase (week 1-9), including 9 weekly peer-led group sessions (90min) and four one-on-one coaching sessions (60min); and~2. Follow-up Intervention Phase (weeks 10-24),consisting of 3 monthly group sessions (90min) and bi-weekly phone check-ins to provide ongoing support (15-20min).~Key intervention components:~1. Peer-led group sessions include personal stories of financial empowerment; practical information about available financial supports; basic financial coaching and mutual support/ accountability (e.g., goal/action check-ins);~2. One-on-one peer coaching sessions (throughout 24 weeks) to help participants identify their personal financial stressors and facilitate a personalized Financial Wellness Action Plan.~3. Support to navigate and access financial supports in the community (e.g., financial counseling, free tax prep, housing eviction prevention, debt relief).
Study: NCT04913740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ointment and dressing for external use
Description: 1. pay attention to the protection of exposed skin, so that it is local dry.~2. Do a good job of facial moisturizing work before work use moisturizing ointment, more durable and non-irritating cream or emulsion, such as vitamin E cream, petroleum jelly, to do a good job of moisturizing work.~3. Use appropriate dressing to avoid direct contact between the mask and the skin, and select the appropriate type of protective device; Reduce friction by applying foam patches, hydrocolloidal dressings, and empleters to the hair area. However, it should be noted that it must be confirmed that airtightness is good and that the protective effect is still the primary purpose of the medical staff.~4. After work, avoid using irritants to clean the face, and massage local skin with skin moisturizer; (5) If severe skin damage occurs, treat it as prescribed by the doctor
Study: NCT06507683

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: simultaneous integrated boost intensity-modulated radiation therapy combined with ripretinib
Description: A cumulative radiation dose of 50 to 70 Gy is administered in 25-30 fractions, 5 fractions per week, to the target lesion(s).~ripretinib: oral 150mg QD
Study: NCT06287307

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be used in the allocated group in addition to our lifestyle program for the duration of 68 weeks in total.
Study: NCT06520930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: breathing exercise therapy
Description: Description: The breathing exercises to be applied were taught to each pregnant woman face to face with one-on-one training. The taught practice was then repeated by the pregnant woman and the researcher together. In the next step, pregnant women were asked to perform the application themselves. In this way, it was determined whether individual breathing exercise practices were performed correctly and effectively. After the one-on-one training was completed, the pregnant women were divided into groups of maximum six people and breathing exercise exercises were performed 7 days a week, once a day and once a week face-to-face for 8 weeks. Each session lasted approximately 45 minutes. For 8 weeks, a short reminder message was sent to pregnant women every morning to ensure that they did not interrupt their daily breathing exercise practices, and they were called in the evening to check whether they had performed the application correctly and whether they had any problems.
Study: NCT04627428

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RPESC-RPE-4W
Description: RPESC-RPE-4W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RPESC-RPE-4W
Description: RPESC-RPE-4W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RPESC-RPE-4W
Description: RPESC-RPE-4W
Study: NCT05022212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LACTIN-V
Description: administered vaginally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered vaginally
Study: NCT06226181

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dacryocystorhinostomy and amniotic membrane
Description: Dacryocystorhinostomy surgery with amniotic membrane placement on the osteotomy site.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional dacryocystorhinostomy
Description: Conventional dacryocystorhinostomy surgery without adding amniotic membrane
Study: NCT06116630

Intervention type: DIAGNOSTIC_TEST
Intervention: DCE-MRI
Description: Both groups will undergo DCE-MRIs.

Intervention type: DIAGNOSTIC_TEST
Intervention: DCE-MRI
Description: Both groups will undergo DCE-MRIs.
Study: NCT04881487

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Additional stereotactic body radiation therapy
Description: 5 fractions of 8 Gray stereotactic body radiation therapy in addition to standard of care.
Study: NCT05682612

Intervention type: OTHER
Intervention: outcome
Description: hospital survivors and nonsurvivors

Intervention type: OTHER
Intervention: outcome
Description: hospital survivors and nonsurvivors

Intervention type: OTHER
Intervention: Subtype of COVID-19
Description: Different subtype of COVID-19

Intervention type: OTHER
Intervention: Subtype of COVID-19
Description: Different subtype of COVID-19
Study: NCT04892537

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Sinus Reducer
Description: Coronary Sinus Reducer implantation according to standard clinical protocols

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Procedure
Description: A placebo procedure involving venous sheath implantation in the right internal jugular vein without proceeding to CSR implantation
Study: NCT06287307

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]
Description: The semaglutide will be used in the allocated group in addition to our lifestyle program for the duration of 68 weeks in total.
Study: NCT06507917

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: anal swabbing
Description: anal swabbing

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: anal swabbing
Description: anal swabbing
Study: NCT05435118

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMONO + audiovisuals tool
Description: EMONO + use of audiovisuals tool on smartphone or tablet
Study: NCT05013788

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Media Enhanced Education
Description: Along with usual asthma education received,participants will receive asthma education via various social media platforms ,Facebook, Twitter, Instagram, and/or Snapchat. Topics of education will include background on asthma and pathophysiology, asthma severity classification, asthma triggers, different medications and indications for when to take them, how to use an inhaler technique, and symptom monitoring.Online resources from the American Lung Association and the National Asthma Education and Prevention Program will also be posted.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Asthma Education
Description: For patients who are admitted to Children's Memorial Hermann for asthma exacerbation, asthma education is provided to patients and families on the day of discharge by the nurse and respiratory therapist on triggers, Signs \& Symptoms, Medication Use, Medication Delivery, Peak Flow, Zones and how to respond to each, and Cleaning equipment.Nursing staff are responsible for printing out education sheets to give to patients and showing an education video that is 20 minutes long. An asthma action plan are given to families on discharge. Patients that are discharged from the emergency room are given the same educational materials by the nurses and/or respiratory therapists except for the asthma video. Patients receive a variable amount of asthma education when going to usual clinic visits. The education provided is dependent on the provider, and usually limited in length to the time of the visit
Study: NCT06092775

Intervention type: DEVICE
Intervention: DEXA scan,X_ray
Description: DEXA scan detect osteoporosis~,X_ray show subclinical vertebral fractures

Intervention type: DEVICE
Intervention: DEXA scan,X_ray
Description: DEXA scan detect osteoporosis~,X_ray show subclinical vertebral fractures

Intervention type: DEVICE
Intervention: DEXA scan,X_ray
Description: DEXA scan detect osteoporosis~,X_ray show subclinical vertebral fractures